Terms: = Brain cancer AND ER, estrogen receptor
1168 results:
1. Inhibition of signaling protein ERN1 increases the sensitivity of serine synthesis gene expressions to glucose and glutamine deprivations in U87MG glioblastoma cells.
Minchenko OH; Sliusar MY; Khita OO; Minchenko DO; Viletska YM; Halkin OV; Levadna LO; Cherednychenko AA; Khikhlo YP
Endocr Regul; 2024 Jan; 58(1):91-100. PubMed ID: 38656254
[No Abstract] [Full Text] [Related]
2. Community cohesion looseness in gene networks reveals individualized drug targets and resistance.
Wang S; Lee D
Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38622359
[TBL] [Abstract] [Full Text] [Related]
3. Design and methods of the mobile assessment of cognition, environment, and sleep (MACES) feasibility study in newly diagnosed breast cancer patients.
Derbes R; Hakun J; Elbich D; Master L; Berenbaum S; Huang X; Buxton OM; Chang AM; Truica CI; Sturgeon KM
Sci Rep; 2024 Apr; 14(1):8338. PubMed ID: 38594369
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Roussot N; Constantin G; Desmoulins I; Bergeron A; Arnould L; Beltjens F; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Jacinto S; Michel E; Amet A; Coutant C; Costa B; Jouannaud C; Deblock M; Levy C; Ferrero JM; Kerbrat P; Brain E; Mouret-Reynier MA; Coudert B; Bertaut A; Ladoire S
Eur J Cancer; 2024 May; 202():114037. PubMed ID: 38554542
[TBL] [Abstract] [Full Text] [Related]
5. Human Epidermal Growth Factor receptor 2-Low Breast cancer brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
Chehade R; Nofech-Mozes S; Plotkin A; Fan KY; Das S; Sahgal A; Moravan V; Jerzak KJ
JCO Precis Oncol; 2024 Mar; 8():e2300487. PubMed ID: 38547418
[TBL] [Abstract] [Full Text] [Related]
6. Protecting the brain: Novel Strategies for Preventing Breast cancer brain Metastases through Selective estrogen receptor β Agonists and In Vitro Blood-brain Barrier Models.
Kirchner J; Völker E; Shityakov S; Saji S; Förster CY
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542355
[TBL] [Abstract] [Full Text] [Related]
7. estrogen-receptor status determines differential regulation of α1- and α2-adrenoceptor-mediated cell survival, angiogenesis, and intracellular signaling responses in breast cancer cell lines.
Priyanka HP; Pratap UP; Nair RS; Vasantharekha R; ThyagaRajan S
Med Oncol; 2024 Mar; 41(5):92. PubMed ID: 38526769
[TBL] [Abstract] [Full Text] [Related]
8. Systematic identification of a synthetic lethal interaction in brain-metastatic lung adenocarcinoma.
Moon JW; Hong BJ; Kim SK; Park MS; Lee H; Lee J; Kim MY
Cancer Lett; 2024 Apr; 588():216781. PubMed ID: 38494150
[TBL] [Abstract] [Full Text] [Related]
9. Effectively α-Terpineol Suppresses Glioblastoma Aggressive Behavior and Downregulates KDELC2 Expression.
Jin JS; Chou JM; Tsai WC; Chen YC; Chen Y; Ong JR; Tsai YL
Phytomedicine; 2024 May; 127():155471. PubMed ID: 38452695
[TBL] [Abstract] [Full Text] [Related]
10. Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis.
Vasseur A; Cabel L; Hego C; Takka W; Trabelsi Grati O; Renouf B; Lerebours F; Loirat D; Brain E; Cottu P; Sablin MP; Pierga JY; Callens C; Renault S; Bidard FC
Oncogene; 2024 Apr; 43(16):1214-1222. PubMed ID: 38413796
[TBL] [Abstract] [Full Text] [Related]
11. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
[TBL] [Abstract] [Full Text] [Related]
12. Rare germline mutation and MSH2-&MSH6 + expression in a double primary carcinoma of colorectal carcinoma and endometrial carcinoma: a case report.
Zhang T; Huang X; Liu W; Ling X; Su Z; Huang M; Che S
Diagn Pathol; 2024 Jan; 19(1):25. PubMed ID: 38297350
[TBL] [Abstract] [Full Text] [Related]
13. Profiling of Unfolded Protein Response Markers and Effect of IRE1α-specific Inhibitor in Pituitary Neuroendocrine Tumor.
Morita S; Uraki S; Ariyasu H; Tsuji T; Doi A; Furuta H; Yamoto T; Nakao N; Akamizu T; Matsuoka TA
Endocrinology; 2024 Feb; 165(4):. PubMed ID: 38289718
[TBL] [Abstract] [Full Text] [Related]
14. MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection.
Meyer M; Parpoulas C; Barthélémy T; Becker JP; Charoentong P; Lyu Y; Börsig S; Bulbuc N; Tessmer C; Weinacht L; Ibberson D; Schmidt P; Pipkorn R; Eichmüller SB; Steinberger P; Lindner K; Poschke I; Platten M; Fröhling S; Riemer AB; Hassel JC; Roberti MP; Jäger D; Zörnig I; Momburg F
Front Immunol; 2023; 14():1294565. PubMed ID: 38239352
[TBL] [Abstract] [Full Text] [Related]
15. Combination of Palbociclib and Endocrine Therapy in Hormone receptor-Positive and Human Epidermal Growth Factor receptor 2-Negative Metastatic Breast cancer With or Without brain Metastases.
Zhang Q; Lan X; Huang J; Xie X; Chen L; Song L; Bai X; Chen X; Jing H; Du C
Technol Cancer Res Treat; 2024; 23():15330338231206986. PubMed ID: 38233376
[TBL] [Abstract] [Full Text] [Related]
16. Heterozygous mutations in the C-terminal domain of COPA underlie a complex autoinflammatory syndrome.
Delafontaine S; Iannuzzo A; Bigley TM; Mylemans B; Rana R; Baatsen P; Poli MC; Rymen D; Jansen K; Mekahli D; Casteels I; Cassiman C; Demaerel P; Lepelley A; Frémond ML; Schrijvers R; Bossuyt X; Vints K; Huybrechts W; Tacine R; Willekens K; Corveleyn A; Boeckx B; Baggio M; Ehlers L; Munck S; Lambrechts D; Voet A; Moens L; Bucciol G; Cooper MA; Davis CM; Delon J; Meyts I
J Clin Invest; 2024 Jan; 134(4):. PubMed ID: 38175705
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic nomograms for breast cancer with lung metastasis: a SEER-based population study.
Xie Y; Lei C; Ma Y; Li Y; Yang M; Zhang Y; Law KN; Wang N; Qu S
BMC Womens Health; 2024 Jan; 24(1):16. PubMed ID: 38172874
[TBL] [Abstract] [Full Text] [Related]
18. Disruption of MAM integrity in mutant FUS oligodendroglial progenitors from hiPSCs.
Zhu Y; Burg T; Neyrinck K; Vervliet T; Nami F; Vervoort E; Ahuja K; Sassano ML; Chai YC; Tharkeshwar AK; De Smedt J; Hu H; Bultynck G; Agostinis P; Swinnen JV; Van Den Bosch L; da Costa RFM; Verfaillie C
Acta Neuropathol; 2024 Jan; 147(1):6. PubMed ID: 38170217
[TBL] [Abstract] [Full Text] [Related]
19. IRE1 endoribonuclease signaling promotes myeloid cell infiltration in glioblastoma.
Obacz J; Archambeau J; Lafont E; Nivet M; Martin S; Aubry M; Voutetakis K; Pineau R; Boniface R; Sicari D; Pelizzari-Raymundo D; Ghukasyan G; McGrath E; Vlachavas EI; Le Gallo M; Le Reste PJ; Barroso K; Fainsod-Levi T; Obiedat A; Granot Z; Tirosh B; Samal J; Pandit A; Négroni L; Soriano N; Monnier A; Mosser J; Chatziioannou A; Quillien V; Chevet E; Avril T
Neuro Oncol; 2024 May; 26(5):858-871. PubMed ID: 38153426
[TBL] [Abstract] [Full Text] [Related]
20. Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics.
Sokolov D; Sharda N; Banerjee A; Denisenko K; Basalious EB; Shukla H; Waddell J; Hamdy NM; Banerjee A
Curr Pharm Des; 2024; 30(1):31-47. PubMed ID: 38151840
[TBL] [Abstract] [Full Text] [Related]
[Next]
